International study on Chronic Myeloid Leukemia in children

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to describe and characterize Chronic Myeloid Leukemia (CML) in a large cohort of pediatric patients. It focuses on children and adolescents diagnosed with Philadelphia positive and/or BCR-ABL positive CML, collecting data on treatment outcomes and side effects. The study is conducted internationally, involving multiple institutions to gather comprehensive epidemiological information that is currently lacking in this age group. By documenting the characteristics of CML in children, the study seeks to improve understanding and management of this rare disease.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* patients less than 18 years of age
* diagnosed Philadelphia positive and/or BCR-ABL positive Chronic Myeloid Leukemia (CML) all phases

Exclusion Criteria:

* patients more than 18 years of age at diagnosis of CML

Where it's running

• St. Anna Children's Cancer Research Institute and St. Anna Children's Hospital
  Vienna, Austria Recruiting
• Belarussian Reseach Center for Pediatric Oncology and hematology (BRCPOH)
  Minsk, Belarus Recruiting
• University Hospital of Ghent
  Ghent, Belgium Recruiting
• Instituto de Oncologia Pediatrica
  São Paulo, Brazil Recruiting
• Prince of Wales Hospital
  Hong Kong, China Recruiting
• Children's Hospital Zagreb
  Zagreb, Croatia Recruiting

Study contacts

• Principal investigator: Frederic MILLOT, MD — Poitiers University Hospital
• Study coordinator: Frederic MILLOT, MD
• Email: f.millot@chu-poitiers.fr
• Phone: +33 (0)5 49 44 30 78

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dasatinib plus ropeginterferon for newly diagnosed chronic myeloid leukemia in chronic phase

  This study tests whether the drug combination dasatinib and ropeginterferon can help control chronic myeloid leukemia in adults with newly diagnosed disease.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07269470

• Prophylactic DLI-X to Prevent Leukemia Relapse After Transplant

  This first-in-human trial tests a prophylactic DLI-X approach to see if it can prevent relapse after matched sibling or haploidentical stem cell transplant in patients with acute leukemias and related blood disorders.

  Recruiting Phase 1 University of Arizona · Tucson, Arizona · NCT07254793

• Optimizing post-transplant bendamustine plus cyclophosphamide for high‑risk myeloid cancers with a partially mismatched donor

  This trial tests whether giving bendamustine plus cyclophosphamide after transplant (with possible abatacept or ruxolitinib) can reduce dangerous cytokine release and graft‑versus‑host disease for people with high‑risk myeloid malignancies who have a partially HLA‑mismatched donor.

  Recruiting Phase 2 St. Petersburg State Pavlov Medical University · Saint Petersburg · NCT07238712

• CBX-250 for relapsed or refractory myeloid leukemias.

  This will try CBX-250, a new injectable medicine, in people aged 12 and older with relapsed or refractory AML, high-risk MDS, CMML, or CML to see if it can control disease with tolerable side effects.

  Recruiting at 11 sites Phase 1 Crossbow Therapeutics, Inc. · Duarte, California and 10 other locations · NCT06994676

• Olverembatinib monotherapy for adults with newly diagnosed chronic-phase CML

  We are testing whether olverembatinib can control disease and produce deep molecular responses in adults newly diagnosed with chronic-phase CML.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06817720

• Using Sorafenib to Prevent Relapse After Stem Cell Transplantation

  This study is testing if the drug sorafenib can help prevent relapse in patients with high-risk blood cancers after they receive a stem cell transplant.

  Recruiting Phase 2 St. Petersburg State Pavlov Medical University · Saint Petersburg · NCT06532084

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.